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Vascular Effects of the Thrombin Receptor
(Protease-Activated Receptor Type 1) in Humans
Ingibjörg J. Gu mundsdo´ttir, MRCP,* Ninian N. Lang, MRCP,* Nicholas A. Boon, MD, FRCP,†
Christopher A. Ludlam, PHD, FRCP,* David J. Webb, MD, FRCP,* Keith A. Fox, FRCP, FESC,*
David E. Newby, PHD, MRCP*
Edinburgh, United Kingdom
Objectives The purpose of this study was to determine the role of the endothelium in the vascular actions of protease-
activated receptor type 1 (PAR-1) activation in vivo in man.
Background Thrombin is central to the pathophysiology of atherothrombosis. Its cellular actions are mediated via PAR-1.
Protease-activated receptor type 1 activation causes arterial vasodilation, venoconstriction, platelet activation,
and tissue-type plasminogen activator release in man.
Methods Dorsal hand vein diameter was measured in 6 healthy volunteers before and after endothelial denudation.
Forearm arterial blood flow, plasma fibrinolytic factors, and platelet activation were measured in 24 healthy
volunteers during venous occlusion plethysmography. The effects of inhibition of prostacyclin, nitric oxide (NO),
and endothelium-derived hyperpolarizing factor on PAR-1 responses were assessed during coadministration of
aspirin, the “NO clamp” (L-NG-monomethyl arginine and sodium nitroprusside), and tetraethylammonium ion,
respectively.
Results Endothelial denudation did not affect PAR-1–evoked venoconstriction (SFLLRN; 0.05 to 15 nmol/min). Although
aspirin had no effect, SFLLRN-induced vasodilation (5 to 50 nmol/min) was attenuated by the NO clamp (p 
0.0001) and tetraethylammonium ion (p  0.05) and abolished by their combination (p  0.01). The NO clamp
augmented SFLLRN-induced tissue-type plasminogen activator and plasminogen activator inhibitor type 1 anti-
gen (p  0.0001) release, but tetraethylammonium ion and aspirin had no effect. SFLLRN-induced platelet acti-
vation was unaffected by NO or prostacyclin inhibition.
Conclusions Acting via PAR-1, thrombin causes contrasting effects in the human vasculature and has a major interaction
with the endothelium. This highlights the critical importance of endothelial function during acute arterial injury
and intravascular thrombosis, as occurs in cardiovascular events including myocardial infarction and
stroke. (J Am Coll Cardiol 2008;51:1749–56) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.047e
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ahrombin plays a central role in the coagulation cascade and
hrombosis (1). It is one of the most powerful physiological
gonists in the cardiovascular system, and its actions are
undamental to the processes of atherosclerosis and its
hrombotic consequences.
In addition to the enzymatic generation of fibrin, throm-
in stimulates a range of cell types including platelets,
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ingdom. Supported by the British Heart Foundation Junior Research Fellowship
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ritish Medical Association Lansdell and Lawson Research Grant. Professor Fox is
he recipient of grants from Schering-Plough. Drs. Gu mundsdo´ttir and Lang
ontributed equally to this work.P
Manuscript received August 17, 2007; revised manuscript received November 21,
007, accepted December 17, 2007.ndothelial cells, and vascular smooth muscle cells. An
xtensive search for thrombin receptors ultimately culmi-
ated in the identification of a group of G-protein coupled
eceptors termed protease-activated receptors (PARs).
See page 1757
hese receptors are characterized by a unique mechanism of
ctivation whereby the receptor undergoes proteolytic cleav-
ge, unmasking a short peptide sequence that remains
ethered and auto-activates the receptor (2,3). To date, 4
ifferent types of PARs have been identified: PAR-1, -3,
nd -4 are all activated by thrombin; PAR-2 is mainly
ctivated by trypsin but transactivation of PAR-2 by cleaved
AR-1 has been recognized (4,5).
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Thrombin and the Endothelium In Vivo May 6, 2008:1749–56Protease-activated receptor type
1 receptors are the principal
thrombin receptors in man and
extensive studies in small animals
and cell cultures suggest that they
have a diverse and important role
in various organs. Their activation
stimulates a network of G-protein
coupled signaling pathways that
involve phospholipase C, protein
kinase C, calcium release, mitogen-
activated protein kinases, and po-
tassium channels (6,7). However,
there is significant species hetero-
geneity with pre-clinical studies of
limited relevance to man (8). Ex-
ploring the role of PAR-1 recep-
tors in the human vasculature
would deepen our understanding
of the physiological role of throm-
bin and be important in the clini-
cal development of new therapeu-
tic strategies.
To understand the physiolog-
ical actions of thrombin in the
uman vasculature is challenging because direct thrombin
nstillation has the potential to cause acute thrombosis in
itu and hence vascular occlusion. The use of a PAR-1
eceptor agonist, however, permits the direct assessment of
ellular responses to thrombin without the enzymatic acti-
ation of the coagulation cascade and fibrin formation.
sing the short peptide mimetic SFLLRN, we have re-
ently described the in vivo effects of PAR-1 activation in
latelets, endothelium and vascular smooth muscle in man.
or the first time, we were able to show that PAR-1
ctivation has unique and contrasting effects in the human
asculature including arterial dilation, venous constriction,
latelet activation, and tissue-type plasminogen activator
t-PA) release (9). Given the central role of thrombin in the
athophysiology of cardiovascular disease, it is important to
stablish the mechanisms of these PAR-1–mediated effects
nd, in particular, the role of the endothelium. We therefore
et out to explore the role of the endothelium in the vascular
ctions of PAR-1 activation in vivo in man.
ethods
ubjects. A total of 30 healthy nonsmokers (mean age 22
ears; range 19 to 37 years) were recruited into the study.
he study was approved by the local research ethics com-
ittee and conducted in accordance with the Declaration of
elsinki and with the written informed consent of all
olunteers. Participants were screened and excluded for
linically significant conditions including hypertension, hy-
erlipidemia, diabetes mellitus, asthma, and coagulopathy.
Abbreviations
and Acronyms
ANOVA  analysis of
variance
EDHF  endothelium-
derived hyperpolarizing
factor
L-NMMA  L-NG-
monomethyl arginine
citrate
NO  nitric oxide
PAI-1  plasminogen
activator inhibitor type 1
PAR  protease-activated
receptor
PGI2  prostacyclin
SNP  sodium
nitroprusside
TEA  tetraethylammonium
ion
t-PA  tissue-type
plasminogen activator
vWF  von Willebrand
factoro participant had suffered a recent infective or inflamma- bory condition or had taken any medications in the 7 days
rior to the study.
ascular assessments. All studies were carried out in a
uiet, temperature-controlled room (22°C to 24°C). Partic-
pants were semirecumbent (venous studies) or supine (ar-
erial studies) and had abstained from alcohol for 24 h and
rom food and caffeine-containing drinks for at least 4 h
rior to the study.
enous studies. A 23-G needle was sited in a dorsal hand
ein and total infusion rate kept constant at 0.25 ml/min in
ll studies. The hand was supported above the level of the
eart and an upper arm cuff inflated to 40 mm Hg to
bstruct venous return. The internal diameter of the dorsal
and vein was measured by the Aellig technique (10) in 6
ealthy volunteers. In brief, a magnetized lightweight rod
ested on the summit of the infused vein approximately 1
m downstream from the tip of the infusion needle. The rod
asses through the core of a linear variable differential
ransformer supported above the hand by a small tripod.
hanges in diameter of the vein caused vertical displace-
ent of the rod, leading to a linear change in the voltage
enerated by the transformer. This enabled calculation of
bsolute changes in vein size.
ROTOCOL 1. VENOUS EFFECTS OF PAR-1 ACTIVATION. First,
e established the presence of functional endothelium. As
orsal hand veins do not have resting tone, norepinephrine
1 to 128 ng/min) was used to induce 70% reduction in vein
iameter. Once stable venoconstriction was obtained, ace-
ylcholine (1 nmol/min; Novartis Pharmaceuticals UK Ltd,
rimley, United Kingdom) was coinfused with norepineph-
ine for 8 min to demonstrate endothelium-dependent
enodilation and an intact, functional endothelium. Follow-
ng a 20-min saline infusion, the PAR-1 activating peptide,
FLLRN-NH2 (0.05 to 15 nmol/min; Clinalfa AG,
aufelfingen, Switzerland), was administered intravenously
efore a final 20-min saline washout infusion.
ROTOCOL 2. VENOUS EFFECTS OF PAR-1 ACTIVATION FOL-
OWING ENDOTHELIAL DENUDATION. At the end of proto-
ol 1, the endothelium of the venous segment was denuded
s previously described (11). In brief, a second 23-G
utterfly needle was sited 3 to 4 cm downstream from the
ip of the infusion-needle, and this segment of the vein was
solated by the use of occlusion wedges. Distilled water was
nfused through the venous segment at a rate of 5 ml/min
or 15 min, thereby causing endothelial denudation that
ersists for at least 2 days (11). Aspirin (300 mg orally) was
iven 30 min prior to start of the first study and on each of
he 2 subsequent days to prevent venous thrombosis. On the
econd day following denudation, subjects reattended and
rotocol 1 was repeated.
rterial studies. All subjects underwent cannulation of the
rachial artery with a 27-G standard wire steel needle under
ontrolled conditions. The intra-arterial infusion rate was
ept constant at 1 ml/min throughout all studies. Forearm
lood flow was measured in the infused and noninfused arms
y venous occlusion plethysmography using mercury-in-
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May 6, 2008:1749–56 Thrombin and the Endothelium In Vivoilastic strain gauges as described previously (12,13). Supine
eart rate and blood pressure were monitored at intervals
hroughout each study using a semiautomated noninvasive
scillometric sphygmomanometer. Tirofiban (1.25 g/min)
as coinfused during the studies to inhibit potential PAR-1
ctivation-induced platelet aggregation in vivo (9). This
ose of tirofiban does not affect platelet-monocyte binding,
orearm blood flow, or baseline concentration of t-PA (9).
ROTOCOL 3: ROLE OF NITRIC OXIDE AND PROSTACYCLIN IN
AR-1–INDUCED VASODILATION. Forearm blood flow was
easured by venous occlusion plethysmography in response
o brachial artery infusion of SFLLRN (PAR-1 agonist; 5
o 50 nmol/min) with tirofiban (1.25 g/min) in 8 healthy
olunteers on 4 visits using a randomized controlled cross-
ver study employing a 2-by-2 factorial design: with and
ithout aspirin (600 mg orally; to inhibit prostacyclin
PGI2] synthesis) and the “nitric oxide (NO) clamp.”
ssuming total forearm blood flow of 25 ml/min, this will
chieve end-organ concentrations of 0.2 to 2.0 mol/l
FLLRN.
The NO clamp was used to determine the contribution of
O in PAR-1–mediated vascular effects. Following base-
ine intra-arterial tirofiban infusion, the NO synthase in-
ibitor, L-NG-monomethyl arginine citrate (L-NMMA; 8
mol/min), was coinfused. To compensate for L-NMMA-
nduced basal vasoconstriction, forearm blood flow was
eturned to baseline using a titrated dose of exogenous NO
n the form of intrabrachial sodium nitroprusside (SNP; 90
o 900 ng/min). This dose of SNP was coinfused with
-NMMA and continued throughout the study. This
rrangement allows a constant “clamped” delivery of exog-
nous NO while endogenous NO synthase activity is
nhibited.
ROTOCOL 4: ROLE OF CALCIUM-ACTIVATED POTASSIUM
HANNELS/ENDOTHELIUM-DERIVED HYPERPOLARIZING FAC-
OR IN PAR-1–INDUCED VASODILATION. Forearm blood flow
as measured in 8 other healthy volunteers in whom
ntrabrachial SFLLRN (5 to 50 nmol/min), bradykinin (30
o 300 pmol/min), and SNP (2 to 8 g/min) were coinfused
ith either saline placebo or tetraethylammonium ion
TEA) (1 mg/min) on either of 2 visits using a randomized
ouble-blind crossover design. Again, agonists were coin-
used with intra-arterial tirofiban (1.25 g/min), which was
ontinued throughout the study. At the dose used, TEA is
nonselective potassium channel antagonist (14–16).
ROTOCOL 5: ROLE OF ENDOTHELIUM-DEPENDENT VASODI-
ATORS IN PAR-1–INDUCED VASODILATION. In the final se-
ies of studies, TEA or saline placebo was coinfused with
scending doses of bradykinin and SFLLRN in 8 volunteers
sing a randomized double-blind crossover design. In this
eries, endothelium-derived hyperpolarizing factor (EDHF)
ctivity was isolated by inhibiting NO and PGI2 production
n both visits. The NO clamp was employed as described
reviously (protocol 3), and cyclooxygenase activity was
nhibited with a single 600-mg dose of oral aspirin 1 h
efore each study. pLOOD SAMPLING. Seventeen-gauge venous cannulae were
nserted into left and right antecubital fossae. Blood samples
ere drawn simultaneously from each arm at baseline.
lood samples were also drawn before SFLLRN or brady-
inin infusion and after each dose of SFLLRN or bradyki-
in. Blood was collected into acidified buffered citrate
Stabilyte, Biopool International, Umeå, Sweden; for t-PA
ssays) and into citrate (BD Vacutainer, BD UK Ltd,
xford, United Kingdom; for plasminogen activator inhib-
tor type 1 [PAI-1], beta thromboglobulin, and von Wille-
rand factor [vWF] assays). Samples were kept on ice before
entrifugation at 2,000 g for 30 min at 4°C. Platelet-free
lasma was decanted and stored at80°C before assay. Plasma
-PA antigen and activity (t-PA Combi Actibind Elisa Kit,
echnoclone, Vienna, Austria), PAI-1 antigen and activity
Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity,
YPHEN BioMed, Neuville-sur-Oise, France), beta throm-
oglobulin (Asserachrom Btg, Diagnostica Stago, Asnières sur
eine, France), and vWF (Dako, Glostrup, Denmark) concen-
rations were determined by enzyme-linked immunosorbent
ssays. Full blood count was measured at baseline and at the
nd of the study.
LATELET-MONOCYTE BINDING. In protocols 3 and 4, blood
as collected from each arm for determination of platelet-
onocyte binding at baseline and after the highest dose of
FLLRN. Samples of 5 ml of venous blood were collected and
ransferred into a tube containing the direct thrombin inhibi-
or, D-phenylalanyl-L-propyl-L-arginine chloromethylke-
one. Five minutes after sampling, blood was incubated with
ppropriate monoclonal antibodies labeled with fluorochromes
or 20 min and platelet-monocyte aggregates measured as
escribed previously (17).
ata analysis and statistics. Dorsal hand venous (18) and
orearm plethysmographic (12) data were analyzed as de-
cribed previously. Variables are reported as means  SEM
nd analyzed using repeated measures analysis of variance
ANOVA) with post hoc Bonferroni corrections and
-tailed Student t test as appropriate. Statistical analysis was
erformed with GraphPad Prism (Graph Pad Software, San
iego, California) and statistical significance taken at the
% level. The authors had full access to the data and take
esponsibility for its integrity. All authors have read and
greed to the manuscript as written.
esults
ndothelium and PAR-1–induced venoconstriction.
he role of the endothelium in PAR-1–induced vasomotor
ffects was assessed by comparing venous responses before
nd after local endothelial denudation. This was achieved
hrough brief instillation of distilled water in an isolated
orsal hand vein segment. After pre-constriction with
orepinephrine, the presence or absence of functional en-
othelium was confirmed by the coinfusion of acetylcholine
1 nmol/min). Acetylcholine caused venodilation in the
resence of endothelium and venoconstriction in its absence
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Thrombin and the Endothelium In Vivo May 6, 2008:1749–56Fig. 1) (from 35  4% to 55  7% in the presence of
ndothelium versus 33  7% to 18  6% in the absence of
ndothelium; p  0.01 for both; ANOVA). After endothe-
ial denudation, there appeared to be a trend toward
nhanced venoconstriction induced by the PAR-1 activat-
ng peptide, SFLLRN (Fig. 1) (p  0.09; ANOVA).
ndothelium-derived vasodilators and PAR-1–induced
asodilation. SFLLRN caused an increase in forearm
lood flow that was unaffected by PGI2 inhibition with oral
spirin (600 mg) (Fig. 2A). The NO synthase inhibitor,
-NMMA, caused 50% decrease in basal forearm blood
ow (from 3.04 0.37 ml/100ml tissue/min to 1.49 0.19
l/100ml tissue/min; p  0.001). Intrabrachial SNP (90 to
00 ng/min), an exogenous NO donor, was titrated to
estore forearm blood flow back to baseline levels (2.77 
.24 ml/100ml tissue/min; p 0.46 clamp dose SNP versus
aseline; paired Student t test). The inhibition of endoge-
ous NO synthesis by the NO clamp attenuated SFLLRN-
nduced vasodilation (Fig. 2B).
Potassium channel antagonism with TEA (1 mg/min)
id not affect baseline blood flow (p  0.76; data not
hown). It attenuated vasodilation to SFLLRN (Fig. 2C),
ut the combination of PGI2, NO synthase, and potassium
hannel inhibition appeared to abolish SFLLRN-induced
asodilation (Fig. 2D).
Both with and without concurrent NO synthase and PGI2
ynthase inhibition, TEA attenuated, but did not abolish
rterial vasodilation to the control endothelium-dependent
asodilator, bradykinin (Figs. 3A and 3B). Tetraethylammo-
ium ion did not affect endothelium-independent forearm
Figure 1 Dorsal Hand Vein Responses to Acetylcholine and
SFLLRN (After Pre-Constriction With Norepinephrine)
Before (blue triangles) and after (red triangles) endothelial denudation.
p  0.05; NS  nonsignificant (p  0.09); presence versus absence of the
endothelium (analysis of variance).rterial vasodilation to SNP (Fig. 3C). dndothelium-derived vasodilators and PAR-1–induced re-
ease of fibrinolytic and coagulant factors. The SFLLRN
ncreased net t-PA antigen and activity and PAI-1 antigen
elease but did not affect net PAI-1 activity (Fig. 4). This
ncrease was augmented by the NO clamp (Fig. 4) but was
ot affected by aspirin or TEA (data not shown; p  NS;
NOVA). Bradykinin caused a dose-dependent increase in
et t-PA antigen (p  0.05; ANOVA) and activity (p 
.0001; ANOVA) release but did not affect PAI-1 antigen
nd activity release (p  NS for both; ANOVA). Tetraeth-
lammonium ion did not alter bradykinin-induced PAI-1 or
-PA release (p  NS for both; ANOVA). Unpaired
nalysis between the 2 subject groups (protocol 4 vs.
rotocol 5) suggests that the NO clamp did not alter
radykinin-induced t-PA or PAI-1 release (p  NS for all;
NOVA). Neither bradykinin nor SFLLRN affected vWF
elease (data not shown; p  NS; ANOVA).
ndothelium-derived vasodilators and PAR-1–induced
latelet activation. SFLLRN increased platelet-monocyte
inding but this was unaffected by inhibition of NO or
GI2 (Table 1). In contrast, SFLLRN increased beta-
hromboglobulin (p  0.001; ANOVA) that was aug-
ented during the NO clamp (p 0.01; ANOVA) (Fig. 5)
ut unaffected by aspirin (p  NS; ANOVA).
iscussion
hrombin is one of the most powerful physiological ago-
ists in the cardiovascular system, and its actions are
undamental to the processes of atherothrombosis. In a
eries of studies, we have here described the contrasting role
f the endothelium in the PAR-1–mediated vascular actions
f thrombin in vivo in man. Although not providing a major
ontribution to venoconstriction or PAI-1 release, the
ndothelium mediates PAR-1–induced arterial vasodilation
nd t-PA release. Our findings provide clear evidence of a
ajor interaction between the vascular endothelium and
hrombin in vivo in man. Furthermore, it highlights the
ritical importance of endothelial function at the time of
cute arterial injury and intravascular thrombosis, such as
uring acute coronary syndromes.
ole of the endothelium in PAR-1–induced vasomo-
ion. We have previously described the unexpected finding
f PAR-1–induced venoconstriction in man (9). Although
ot caused by platelet aggregation (9), this effect could be
ediated by either a direct action on vascular smooth
uscle or via the release of endothelium-derived vasocon-
trictors, such as endothelin or angiotensin II. To address
his question, we assessed PAR-1 venoconstriction before
nd after endothelial denudation by instillation of distilled
ater. There was a modest trend toward enhanced veno-
onstriction after endothelial denudation, and we cannot
xclude a small contribution from the endothelium that may
lso include the release of venodilatory mediators such as
O. However, PAR-1 continued to induce a markedose-dependent venoconstriction even in the absence of the
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May 6, 2008:1749–56 Thrombin and the Endothelium In Vivondothelium, which suggests a dominant and direct effect of
AR-1 on the vascular smooth muscle cells.
In contrast to effects on the venous circulation, the
AR-1 agonist causes potent arterial vasodilation. This
uggests a different effect on the arterial vasculature that is
ikely to be mediated by the endothelium. It would be
ifficult and ethically challenging to conduct comparable in
ivo endothelial denudation studies in the arterial circula-
ion of man. We chose, therefore, to use a pharmacological
pproach to the inhibition of the 3 main known mediators of
ndothelium-dependent vasodilation: PGI2, NO, and EDHF.
lthough PGI2 inhibition appeared to have no effect, inhibi-
ion of NO and potassium channels both attenuated the
AR-1–induced vasodilation. Consistent with some cross talk
nd compensatory up-regulation, combined inhibition of all
asodilator mechanisms appeared to produce greater inhibi-
ion, if not abolition, of the vasodilator actions of the PAR-1
gonist. This suggests that, unlike the venous circulation,
AR-1–mediated arterial actions are dominated by, and de-
endent on, the vascular endothelium.
AR-1–induced release of endothelium-derived factors.
n addition to vasomotion, PAR-1 has important effects on
he release of endothelium-derived coagulant and fibrino-
ytic factors. In keeping with a wide range of other endo-
Figure 2 SFLLRN-Induced Forearm Arterial Vasodilation
In the presence (red symbols) and absence (blue symbols) of (A) aspirin (square
(analysis of variance [ANOVA]); (B) the nitric oxide (NO) clamp (circles), p  0.0
monium (TEA) (triangles), †p  0.05 in the presence versus the absence of TEA
ence versus the absence of aspirin, the NO clamp, and TEA (ANOVA).helial G-protein coupled receptor dilator agonists (19), we Ponfirmed our earlier findings that the PAR-1 agonist
auses endothelial t-PA release without affecting vWF.
owever, we also report here that SFLLRN-induced t-PA
elease appeared to be augmented by the inhibition of
ndogenous NO production. Smith et al. (20) have reported
imilar findings when they examined bradykinin-evoked
-PA release in the presence and absence of L-NMMA.
ecause t-PA release is independent of NO and cyclooxy-
enase activity, it has been suggested that EDHF is respon-
ible for its release (21). One could speculate that, by
nhibiting NO activity, EDHF is up-regulated, and this
ccounts for the augmented t-PA release induced by
FLLRN in our study and by bradykinin in Smith’s study.
owever, in contrast to TEA’s inhibitory effects on
FLLRN-induced arterial vasodilation, it had no effect on
FLLRN-evoked t-PA release. Similar findings have re-
ently been reported by Muldowney et al. (22) who exam-
ned the role of EDHF in an in vitro model of thrombin-
nduced endothelial t-PA release. A variety of potassium
hannel antagonists, including TEA, had no effect on
hrombin-induced t-PA release, but antagonists of specific
poxyeicosatrienoic acids appeared to inhibit thrombin-
nduced release of t-PA.
Another novel finding in our study was the increase in
 nonsignificant (p  0.53) in the presence versus the absence of aspirin
the presence versus the absence of the NO clamp (ANOVA); (C) tetraethylam-
); and (D) aspirin, the NO clamp, and TEA (diamonds), #p  0.01 in the pres-s), NS
001 in
(ANOVAAI-1 release, especially during NO synthase inhibition. To
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Thrombin and the Endothelium In Vivo May 6, 2008:1749–56ate, there have been no reports of acute increases in plasma
AI-1 concentrations following the administration of en-
othelial agonists, especially using the forearm model (19).
ven though the endothelium is an important source of
AI-1, we believe our findings are consistent with acute
latelet release of PAI-1. There are several reasons to
upport our contention. First, although PAI-1 antigen
oncentrations increased, there was no corresponding rise in
AI-1 activity. Indeed, PAI-1 activity fell during marked
elease of t-PA. Plasminogen activator inhibitor type 1 is
tored in platelet -granules where its activity is very low
5% of the activity seen in plasma) due to the absence of
Figure 3 Bradykinin- and SNP-Induced
Forearm Arterial Vasodilation
Forearm arterial vasodilation induced by (A) bradykinin (squares), (B) bradykinin in
the presence of the NO clamp and aspirin (circles), and (C) sodium nitroprusside
(SNP) (diamonds) in the presence (red symbols) and absence (blue symbols) of
TEA. p  0.05; †p  0.0001; NS  nonsignificant (p  0.41) in the presence
versus the absence of TEA (ANOVA). Abbreviations as in Figure 2.he stabilizing effect of vitronectin. In contrast, we would lnticipate that endothelial-derived PAI-1 would remain
ctive. Second, there was no concurrent rise in vWF confirm-
ng a selective effect on the endothelium with isolated t-PA
elease. Third, we also demonstrated concomitant platelet
ctivation with marked increases in platelet-monocyte binding
nd release of beta-thromboglobulin; the latter is also stored in
he -granules of platelet. Finally, PAR-1–induced PAI-1
elease was augmented during the NO clamp. Nitric oxide has
mportant antiplatelet effects and, in the presence of its inhi-
ition, increased platelet activation may have led to greater
AI-1 release.
linical relevance. Until recently, it has not been possible
o undertake a safe clinical assessment of the vasomotor
ffects of thrombin due to its potent stimulatory effects upon
he coagulation cascade. However, the synthetic activating
eptide, SFLLRN, allows the examination of activation of
he human PAR-1 thrombin receptor without activation of
he coagulation cascade. This also permits the assessment
f PAR-1 actions independent of the potential confounding
ffects that the activated coagulation pathway may have
pon vascular responses.
We have demonstrated that many of the arterial effects of
he PAR-1 agonist are dependent on, and mediated through,
he endothelium and can therefore be used to assess endothelial
unction. To date, many endothelial G-protein-coupled recep-
or agonists have been used to assess endothelial function, such
s acetylcholine and substance P. However, such agents are
nlikely to have a major role in vascular physiology or patho-
hysiology and, as pharmacological tools, their relevance to the
ssessment of endothelial vasomotor function has limitations.
s a more physiologically relevant tool, the PAR-1 agonist
ay be a more appropriate method of assessing endothelial
unction in the context of atherothrombosis. These novel
nsights into the vascular actions of the PAR-1 agonist will
ot only contribute to our understanding of human physi-
logy and pathophysiology but also promise to inform the
linical development of novel antithrombotic PAR-1 recep-
or antagonists.
tudy limitations. We chose to use SFLLRN as a PAR-1
gonist for several reasons. First, the vast majority of
ublished work has employed SFLLRN as a PAR-1 acti-
ating peptide, and its actions have been widely character-
zed. Second, we have previous clinical experience of the in
ivo actions of SFLLRN and this has facilitated the com-
arability of our current findings with our previous “first-
nto-man” clinical studies. Finally, SFLLRN is identical to
he active cleaved sequence of the human PAR-1 receptor
nd represents a more physiologically relevant agonist of the
eceptor.
Although SFLLRN is selective for the PAR-1 recep-
or, it does have agonist activity at the PAR-2 receptor:
-fold greater selectivity for the PAR-1 versus PAR-2
eceptor (23). Therefore, there remains a possibility that
contribution of the observed actions of SFLLRN may
epresent PAR-2 antagonism. However, we do not be-
ieve this is likely for several reasons. First, we have
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May 6, 2008:1749–56 Thrombin and the Endothelium In Vivoreviously shown that SLIGKV, a highly selective PAR-2
ctivating peptide, causes only modest arterial vasodilation
t high doses and, in contrast to PAR-1 activation, causes
arked venodilation and does not cause arterial t-PA
elease in vivo (24). Moreover, the predicted end-organ
oncentration of the highest dose of SFLLRN used in our
urrent and previous studies is 4-fold lower than the median
ffective dose for the PAR-2 receptor (23). However, we do
ccept that, in future studies, consideration should be given
o the use of the more selective PAR-1 activating peptide,
FLLRN (23,25).
The role of NO in bradykinin-induced t-PA release
emains controversial (19) and the present study has not
efinitively addressed this issue. Although NO donors do
ot induce t-PA release (26,27), inhibition of NO synthesis
as been reported either to have no effect (21), or to increase
20), bradykinin-induced t-PA release. Our own unpaired
nalysis of data from different subject populations is in
eeping with the findings of Brown et al. (21) and suggests
Figure 4 SFLLRN-Induced t-PA and PAI-1 Release
Net tissue-type plasminogen activator (t-PA) (squares) and plasminogen activator i
response to intrabrachial SFLLRN in the presence (red symbols) and absence (blu
presence versus the absence of the NO clamp (ANOVA). Abbreviations as in Figure
Percent Platelet-Monocyte Binding
Table 1 Percent Platelet-Monocyte Binding
Baseline
Infused Arm Non
Placebo 16.62 4.38 12
Aspirin only 14.43 1.95 14
NO clamp only 11.84 1.52 16
Aspirin  NO clamp 12.19 1.66 14*p  0.001 versus baseline (analysis of variance).
NO  nitric oxide.hat bradykinin-induced t-PA release is unaffected by either
O or prostaglandin inhibition. Further research into the
athways involved in bradykinin-induced t-PA release is
eeded to clarify the role of NO and other potential
ediators.
onclusions
rotease-activated receptor type 1 activation causes contrasting
ffects in the human vasculature. It causes endothelium-
ependent arterial vasodilation and t-PA release as well as
ndothelium-independent venoconstriction and PAI-1 release.
here appears to be a major interaction between the vascular
ndothelium and thrombin’s PAR-1–mediated effects in vivo
n man. This highlights the critical importance of endothelial
unction particularly at the time of acute arterial injury and
ntravascular thrombosis, such as occurs during many acute
ardiovascular events including myocardial infarction and
troke.
r type 1 (PAI-1) (circles) antigen (solid lines) and activity (dashed lines) in
bols) of the NO clamp. p  0.0001; NS  nonsignificant (p  0.075) in the
After SFLLRN
Arm Infused Arm Noninfused Arm
1.61 75.89 5.09* 41.36 6.86*
3.61 72.07 5.41* 49.67 7.82*
3.23 81.21 5.68* 46.42 7.42*
2.02 82.85 5.57* 46.63 6.48*nhibito
e sym
2.infused
.48
.87
.95
.15
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